Objective: The aim of this study was to measure the effectiveness, safety, and use of anti-tumor necrosis Factor (TNF) therapy in pediatric inflammatory bowel disease in the United Kingdom (UK). Methods: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment þ/or the Paediatric Crohn Disease Activity Index. Results: A total of 37 centers participated (23/25 specialist pediatric inflammatory bowel disease sites). A total of 524 patients were included: 429 with Crohn disease (CD), 76 with ulcerative colitis (UC), and 19 with IBD unclassified (IBDU). Eighty-seven percent (488/562) of anti-TNF was infliximab; commonest indication was active luminal CD 77% (330/429) or chronic refractory UC/IBDU 56% (53/95); 79% (445/562) had concomitant co-immunosuppression. In CD (267/429 male), median time from diagnosis to treatment was 1.42 years (interquartile range 0.63-2.97). Disease (at initiation) was moderate or severe in 91% (156/171) by Physician Global Assessment compared to 41% (88/217) by Paediatric Crohn Disease Activity Index (Kappa (k) 0.28 ¼ only ''fair agreement''; P < 0.001. Where documented, 77% (53/69) of patients with CD responded to induction; and65%(46/71)enteredremission.Atotalof2287infusionsand301.96yearsof patient' follow-up (n ¼ 385) are represented; adverse events affected 3% (49/ 1587) infliximab and 2% (2/98) adalimumab infusions (no deaths or malignancies). Peri-anal abscess drainage was less common after anti-TNF initiation (CD), that is 26% (27/102) before, 7% (3/42) after (P ¼ 0.01); however, pre and post anti-TNF data collection was not over equal time periods. Conclusions: Anti-TNFs are effective treatments, usually given with thiopurine co-immunosuppression. This study highlights deficiencies in formal documentation of effect and disparity between disease severity scoring tools, which need to be addressed to improve ongoing patient care.
(JPGN 2018;66: 274-280)
What Is Known
Anti-tumor necrosis factor therapy is a very effective treatment for refractory pediatric inflammatory bowel disease.
There are concerns about use of co-immunosuppression and potential increased lymphoma risk. Physician Global Assessment and Pediatric Crohn's Disease Activity Index are frequently used measures of disease activity.
What Is New
Formal documentation of response/remission rates to induction anti-tumor necrosis factor therapy is infrequent. The majority of patients in this large cohort are receiving combination therapy, usually with thiopurines. There was disparity between Physician Global Assessment and Pediatric Crohn Disease Activity Index scores; weighted Pediatric Crohn Disease Activity Index is suggested as an alternative.
T he inflammatory bowel diseases (IBD), comprising Crohn disease (CD), ulcerative colitis (UC), and IBD unclassified (IBDU), are increasing in incidence and prevalence, notably in the pediatric population (1) . Pediatric care has been revolutionized in the last decade by the widespread introduction of antitumor necrosis factor (anti-TNF) therapy, both infliximab (IFX) and adalimumab (ADA); registration clinical trials have shown these agents to be effective where other therapies have failed (2, 3) . Pediatric-onset IBD (PIBD) tends to be more extensive at diagnosis and aggressive in behavior (4, 5) and use of anti-TNF therapy is proportionately greater in the pediatric population compared to adults (20% in adolescents vs 8% in adults in 1 case-control study) (6) .
IFX and ADA have been licensed for use in PIBD in the UK since 2010 and 2013 respectively; UK survey data have demonstrated effectiveness in treating refractory disease while highlighting the potential for serious adverse effects (7, 8) . Scottish data on 132 PIBD patients treated with biologics during a decade show response rates of 87% with IFX (48% remission) and 76% with ADA (35% remission) replicating previous safety issues, especially serious infection (9) .
The UK IBD audit is a national gastrointestinal audit first commenced in 2006 (reporting in 2008) . Reports are available online at www.rcplondon.ac.uk/ibd. Data have previously been published on the outcomes of pediatric and adult patients with UC (10, 11) . We aimed to collect data on anti-TNF therapies in UK PIBD practice to assess effectiveness, safety, and appropriate use (according to national guidelines) in clinical practice. Unselected, large-scale national data will help quantify and categorize adverse events where real-life clinical data are lacking.
METHODS
Sites (either a single hospital or a represented health board or trust) were eligible to participate in the audit if they prescribe and administer anti-TNF therapies to their patients with IBD, on a voluntary basis. A total of 37 sites participated, including 23 of 25 specialist PIBD sites, representing a broad subset of PIBD patients across the UK.
Children with a diagnosis of IBD who were 18 years or younger when newly started receving anti-TNF therapy for IBD from September 12, 2011 were eligible for inclusion. Patients already receiving anti-TNF therapy before this date were excluded. Data were collected prospectively and entered into a bespoke webbased database, with security maintained through local site codes and the lead clinician for the site authorizing local access. All treatment decisions and data entry were at the discretion of the treating physician. Data capture for the results included here ended on February 28, 2014.
Demographic details were pseudoanonymized at the point of data entry and identifiable only to the participating site. IBD disease details were phenotyped according to Montreal criteria for disease location and behavior (12) . Physician Global Assessment (PGA), Pediatric Crohn Disease Activity Index (PCDAI) or Paediatric Ulcerative Colitis Activity Index (PUCAI) scores were collected at initial and follow-up treatments, along with details of co morbidities and any surgery (13) (14) (15) . A full list of all data items collected is available on request.
Acute infusion reactions were as decided by the treating clinical team responsible for the patient; no specific guidance on specific timing was given to teams. Each follow-up treatment relates to an initial submission and records outcome as intention to continue or stop; response with or without remission using reduction in PCDAI/PUCAI or Harvey Bradshaw Index (16) . Unlimited numbers of follow-up treatments are permitted and any adverse events recorded. Poor response was used to describe those patients with no or limited response to anti-TNF treatment, which included primary nonresponders.
Details of IBD-related surgery can be added at any time, along with any escalation of treatment at each initial or follow-up treatment. Patient-reported Outcome Measures (PROM) data were collected using the IMPACT-III questionnaire (17) (18) (19) at initiation and subsequently.
Some children received treatment with multiple biologics resulting in more initial treatments than patients. As the number of submissions per patient is variable (eg, multiple initial or follow-up treatments), the denominators presented vary considerably; results tables should therefore be scrutinized carefully in conjunction with any explanatory notes for accurate interpretation.
Guidance on the use of anti-TNF therapy in the UK comes via the National Institute for Health and Care Excellence and the Scottish Medicines Consortium (SMC). National Institute for Health and Care Excellence Technology Appraisals TA187 (CD) and TA329 (UC) recommend IFX (and ADA) within its licensed indication as an option for ''the treatment of people ages 6 to 17 years with severe active disease who have not adequately responded to conventional therapy (including corticosteroids, immunomodulators, and exclusive enteral nutrition [CD]), or who cannot tolerate or have contraindications to conventional therapy'' (7, 20) . Data were collected on disease type and severity as well as previous therapies to assess prescribing against these criteria.
Selected data, including demographics, disease location, and response to treatment were compared to data reported in the adult arm of the audit from the same time period, which can be seen at www.rcplondon.ac.uk/ibd (21 trademarks or trademarks of SAS Institute Inc., Cary, NC. x 2 test and the kappa statistic were used to examine categorical data; the Mann-Whitney U test was used to examine continuous data; Kolmogorov-Smirnov (KS) test was used to analyze PROM data. Kappa statistic is expressed as per the boundaries described by Landis and Koch; range is from''poor/slight'' agreement (k 0.2) through ''fair,'' ''moderate,'' and ''substantial,'' to ''almost perfect'' agreement (k 0.81-1.00). A P value of <0.05 was considered statistically significant.
Ethical Considerations
As an audit of clinical practice, ethical permission was not applied for.
RESULTS

Overview
By February 28, 2014, demographic submissions were entered on 817 individual pediatric patients; 156 patients with no initial treatment details entered were excluded leaving 661 patients with 746 initial treatments (some patients were treated with >1 anti-TNF). Further exclusions resulted in final analysis on 524 patients (429 CD, 76 UC, and 19 IBDU) with 562 initial treatments ( Fig. 1 
Ulcerative Colitis
The majority of patients had extensive disease (E3) at initiation ( (Table 2) . Cross-tabulation had a Kappa statistic of 0.58 indicating ''moderate'' agreement (0.41-0.60) between PGA and PUCAI (22) .
There was 97% follow-up for ongoing IFX treatments (168/ 174), median 94 days (IQR 21, 215), and 83% (5/6) for ongoing ADA treatments, median 130 days (IQR 114, 304). 12% treatments were stopped (21/173), with poor response or loss of response equally accounting for 76% (16/21) . Where PGA was documented, disease severity (n ¼ 100) improved in most at follow-up (n ¼ 38) ( Table 2) .
IBD Unclassified
Ninety-five percent (20/21) of IBDU patients had extensive disease (E3) at initiation. Acute severe and chronic refractory IBDU accounted for an equal proportion of treatments. There was 97% follow-up for ongoing anti-TNF at a median of 44 days (IQR 14, 98) for IFX. Sixteen percent of treatments were stopped (n ¼ 5) owing to poor response (2/5), adverse effects (2/5), loss of response (1/5). Disease severity where recorded at follow-up was mild in 10%, moderate in 76%, and severe in 14% (n ¼ 21), compared to 0% mild, 22% moderate, and 78% severe at initiation (n ¼ 9).
Disease severity was moderate to severe in 100% (9/9) IBDU at initiation by PGA, where documented, compared with 62% (5/8) by PUCAI.
Response and Remission
Response to induction was infrequently formally recorded; 17% (89/524) all IBD (CD 74/429, UC 12/76, IBDU 3/19). Seventyfive percent (67/89) of patients responded (fall in PCDAI !15, fall 
Surgery
A total of 105 pediatric patients had surgery involving 156 IBD-related surgical procedures. There was no significant difference between surgery in the 6 months pre and post initiating biologic; 7% (36/524) pre and 5% (27/524) post (P ¼ 0.30). Eighty-seven percent (136/156) procedures were in patients with CD, 8% (13/156) in patients with UC, and 5% (7/156) in patients with IBDU. The commonest surgical procedure in UC/IBDU was subtotal colectomy with ileostomy. The common most procedures (by disease type) are detailed in Supplemental Digital Content, Table 2 , http://links.lww.com/MPG/B44. The commonest procedure overall was examination under anesthetic of fistula, 24% (40/166) of all surgical procedures, 27% (39/144) CD procedures. Drainage of perianal abscess was significantly less common in CD after anti-TNF than before (28% [27/96] vs 8% [3/39]; P ¼ 0.01). The time period, however, of data collection was not equal pre and post anti-TNF and was variable from patient to patient. In total, 16% (12/74) of patients with UC went on to have colectomy (Supplemental Digital Content, Table 2 , http://links.lww.com/MPG/B44). 
Safety Data
Pretreatment Screening
Tuberculosis (TB) screening was carried out: 97% (478/493) had at least 1 test for TB; 88% (433/492) patients had a chest x-ray, 47% (224/481) a gamma interferon TB test, and 3% (15/469) had a Mantoux test. Seventy-one percent (343/485) patients were screened for Varicella immunity, 46% (221/482) for hepatitis B infection, 37% (176/480) for Hepatitis C, and 12% (57/476) were screened for HIV infection.
Comparison to Adult Data
Comparison was made to data from the adult biologic audit, which ran during the same time period. There was a male preponderance in the pediatric cohort, with more extensive disease distribution and shorter time from diagnosis to anti-TNF initiation.
Response and remission rates were comparable, but more children were co-immunosuppressed at the time of starting anti-TNF (Supplemental Digital Content, Table 4 , http://links.lww.com/ MPG/B46).
Patient-reported Outcome Measures
Nineteen percent of patients (98/524) had IMPACT-III scores recorded at baseline with 33% (32/98) with a repeat at follow-up (Supplemental Digital Content, Table 5 
DISCUSSION
This large cohort of pediatric patients receiving anti-TNF therapy during a 2.46-year period gives a snapshot of use in real-life clinical practice for PIBD across the UK. Overall response and remission rates are good (75% patients responding and 60% achieving remission), but one of the key outcomes is that formal documentation of this is infrequently done (17% patients). This is despite patients going on to receive maintenance therapy after their induction course. We highlight the need for formal postinduction assessment of response to determine the need for on-going treatment and suggest a validated scoring system as the best method. Failure to do this formally is highly concerning; patients may continue to receive treatment that is failing or not have appropriate investigations performed, for example, Trough-level determination.
Complete accrual of all anti-TNF use, effectiveness, and safety has been published in a nationwide Scottish PIBD registry study, but this only represents 8% of the UK pediatric population (9) . Lower remission rates of 48% and 36% for IFX and ADA, respectively, were reported here, but the period studied was longer, 2000 to 2010, perhaps reflecting early use of anti-TNF when current standard practice, such as maintenance rather than episodic treatment and dose optimization, was not in place (9) . A previous UK survey of ADA for pediatric CD reported a remission rate of 61% at follow-up (8) and the RESEAT study a 65% to 71% clinical response rate at 3 to 12 months of ADA therapy in pediatric CD (24) , which are comparable despite our low documentation rate.
There is a clear discrepancy between PGA and PCDAI scores. Documentation of PCDAI at follow-up was low, as in previous studies, thought potentially due in part to the inclusion of items that are less readily obtained such as height velocity, perianal examination, and laboratory indices (15, 25) . Formal documentation of such data can be seen as a low priority in busy clinical practice. PCDAI was less frequently recorded than PUCAI here, which may support the theory that a simpler score is better used. Recently, the weighted PCDAI (wPCDAI) has been proposed as an alternative measure to the PCDAI and shown to have validity despite the exclusion of hematocrit, abdominal examination, and height velocity as parameters (26) . Replacing PCDAI with wPCDAI in subsequent rounds of the audit may encourage increased completion and thereby facilitate more objective clinical assessment and aid decision-making. An app to allow easy calculation of wPCDAI and documentation was produced as a result of this study. The PUCAI appeared to have better correlation with PGA than PCDAI, in keeping with other studies specifically designed to test this, which shows excellent agreement (15) .
There was a significant reduction in the need for drainage of perianal abscess after initiation with anti-TNF. We note that time periods pre and post initiation were not equal or defined, limiting the strength of any conclusions drawn from this, but we know that perianal disease is recognized as a debilitating CD phenotype and anti-TNFs have been shown to be an effective treatment in large studies (27) . The rate of colectomy in UC patients at 16% is in keeping with adult studies (28, 29) , and the rate of colectomy post anti-TNF in IBDU patients is notable at 21% but numbers are small (4/19) .
Although the follow-up period is relatively short (max 2.46 years), the large number of patients allows us some confidence in the short-term safety profile of the anti-TNF therapies, as 2287 infusions and 302 years of patient follow-up are represented. Infection was the commonest adverse event, in keeping with other published studies (9, 30) and although risks are minimized where possible, total prevention is not achievable. Despite safety concerns about the use of combination therapy and lymphoma risk, it is interesting to note that the majority of patients in this cohort were on combination therapy. Recently published registry data from a very large cohort of pediatric patients (some from the UK) have shown no increased risk of malignancy during longer-term follow-up, supporting the good safety profile of IFX (31), as with previous anti-TNF safety data (32) .
Screening practice is variable; exclusion of TB infection is an obligatory part of guidelines, so there remains room for improvement in the final unscreened 3% (33, 34) . The risk of hepatitis B reactivation is well known, but despite this less than half of patients were screened, highlighting a need to improve on this.
The shortened time from diagnosis to starting anti-TNF in the pediatric population compared to adults is striking; it suggests aggressive progression of disease and rapid cycling though medical therapeutic options, although potentially reflects poorer tolerance of standard treatments and the context of aiming for steroid free remission as quickly as possible to minimize impact on growth, puberty, and education.
It is difficult to draw any meaningful conclusion regarding impact on quality of life (QoL) because of the small numbers of documented PROMs. Completion in subsequent audit rounds should be promoted, as improvement in QoL is an important outcome and cannot be assumed from other markers of response. Of note, significant improvement in QoL using IMPACT 3 in pediatric patients has been recently documented in a formal clinical study (35) .
The main limitation of this study is the variability in completeness of data capture, reflected in the changing denominator for different categories of data. This audit relies on clinical centers finding time to enter patient data and it is often only possible for them to supply the minimum data set. By comparison, it is a major undertaking to capture all biological usage and outcomes in a PIBD population (9) . Follow-up is relatively short; therefore, the ongoing medical and surgical course of those who do not respond is unknown. Its strength however lies in the nationwide collaborative nature of the project and relatively large numbers represented, with >90% of specialist sites participating and the ''real-world'' clinical data, which should mean conclusions that can be drawn are broadly generalizable to the PIBD population. Addressing the major issue of poor documentation of post induction response is likely to result in a significant improvement in the clinical care PIBD patients. The large number of treatments in routine clinical use support anti-TNF therapy as safe and effective in pediatric IBD with the majority of patients achieving response or remission and just 2% of initial infusions and 1% of follow-up infusions associated with acute adverse reactions.
Future audit is increasingly important with biosimilars now licensed for use in PIBD in the UK; generating comparative clinical data on their efficacy and safety profile is essential to evaluate their use, given the current lack of any published evidence in IBD. Ongoing national collaboration would be the best way to achieve this quickly and meaningfully.
